ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced a restructuring of the
U.S. co-promotion and ex-U.S. license and collaboration agreements with
Bayer Schering Pharma AG and Bayer HealthCare relating to RECOTHROM®
Thrombin, topical (Recombinant). Effective January 1, 2010, ZymoGenetics
regains full promotion rights in the United States and all ex-U.S.
rights except in Canada, where Bayer will market and sell the product.
“We intend to seek new licensees to pursue
the development of these markets.”
“The amended agreements with Bayer should benefit ZymoGenetics in a
number of ways,” said Douglas E. Williams, Ph.D., Chief Executive
Officer of ZymoGenetics. “The U.S. marketing and sales operation should
achieve greater efficiency with one sales organization. We plan to
increase the size of our field force to compensate for Bayer’s exit.
However, despite this increase, we expect the change to lower our
selling costs and improve our bottom line, while enabling us to continue
to gain market share.”